Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Drug Discov Ther ; 14(3): 109-116, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-646673

RESUMEN

With the emergence of coronavirus disease 2019 (COVID-19) in late December 2019, many clinical studies on a group of the pre-existing medications have been conducted to treat this disease. The purpose of this review was to compile the clinical evidences on the use of the pre-existing medications and potential therapeutic options for the management of COVID-19. We reviewed the literature to highlight the clinical studies on the use of these medications to be available as a scientific overview for further perspectives. Inadequate clinical evidences are available to be affirmed for the repurposing of old medications, and large scale clinical studies are needed to be carried out to further confirm the use of these agents. The clinical use of these medications should be well explained and follow the framework of Monitored Emergency use of Unregistered Interventions (MEURI) of World Health Organization (WHO).


Asunto(s)
Adenosina Monofosfato/análogos & derivados , Alanina/análogos & derivados , Antivirales/administración & dosificación , Betacoronavirus/efectos de los fármacos , Infecciones por Coronavirus/tratamiento farmacológico , Reposicionamiento de Medicamentos/métodos , Hidroxicloroquina/administración & dosificación , Neumonía Viral/tratamiento farmacológico , Adenosina Monofosfato/administración & dosificación , Alanina/administración & dosificación , Antirreumáticos/administración & dosificación , Betacoronavirus/metabolismo , Ensayos Clínicos como Asunto/métodos , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/diagnóstico , Reposicionamiento de Medicamentos/tendencias , Humanos , Pandemias , Neumonía Viral/sangre , Neumonía Viral/diagnóstico
2.
Eur J Clin Invest ; 50(9): e13342, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-636108

RESUMEN

COVID-19 pandemia is a major concern for patients and healthcare systems. The fear of infection by patients with concomitant rheumatic diseases (either adult or children) and connective tissue diseases is arising worldwide, because of their immunological background and immunological therapies. Analysing the basic biology of single diseases, the data suggest that there is an "immunological umbrella" that seems to protect against the infection, through IFN type 1 and NK cell function. To date, reports from China, United States and Europe did not reveal an higher risk of infection, either for rheumatoid arthritis, juvenile idiopathic arthritis nor for lupus erythematosus. Antimalarials, anti-IL6-Anti-IL6 receptor, anti-IL1, anti-GM-CSF receptor and JAK1/2/3 inhibitors, are under investigation in COVID-dedicated clinical trials to control the inflammation raised by SARS-CoV-2 infection. Initial reports on the occurrence of autoimmune phenomena in the convalescence phase of SARS-CoV-2 infection suggests that the immunological consequences of the infection need to be strictly understood. Reporting of the study conforms to broad EQUATOR guidelines (Simera et al January 2010 issue of EJCI).


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/inmunología , Inmunosupresores/administración & dosificación , Neumonía Viral/epidemiología , Neumonía Viral/inmunología , Enfermedades Reumáticas/epidemiología , Síndrome Respiratorio Agudo Grave/epidemiología , Inmunidad Adaptativa/efectos de los fármacos , Inmunidad Adaptativa/inmunología , Anciano , Antirreumáticos/administración & dosificación , Comorbilidad , Infecciones por Coronavirus/tratamiento farmacológico , Brotes de Enfermedades/estadística & datos numéricos , Femenino , Humanos , Hidroxicloroquina/administración & dosificación , Inmunidad Innata/efectos de los fármacos , Inmunidad Innata/inmunología , Factores Inmunológicos/administración & dosificación , Italia/epidemiología , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/tratamiento farmacológico , Enfermedades Reumáticas/tratamiento farmacológico , Enfermedades Reumáticas/inmunología , Medición de Riesgo , Síndrome Respiratorio Agudo Grave/tratamiento farmacológico , Síndrome Respiratorio Agudo Grave/inmunología
3.
Therapie ; 75(4): 335-342, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-622342

RESUMEN

Since December 2019, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there is a small but significant increased risk of mortality. Among the different treatments, NSAIDs are associated with higher rates of complications, but data for other drugs are conflicting or incomplete. The use of certain drugs for autoimmune inflammatory rheumatisms appears to be a potentially interesting options for the treatment. The rationale for their use is based on the immune system runaway and the secretion of pro-inflammatory cytokines (Il1, IL6, TNFα) in severe forms of the disease. Notably, patients on chloroquine or hydroxychloroquine as a treatment for their autoimmune rheumatic disease are not protected from COVID-19.


Asunto(s)
Enfermedades Autoinmunes/epidemiología , Infecciones por Coronavirus/epidemiología , Neumonía Viral/epidemiología , Enfermedades Reumáticas/epidemiología , Antiinflamatorios no Esteroideos/administración & dosificación , Antirreumáticos/administración & dosificación , Enfermedades Autoinmunes/tratamiento farmacológico , Cloroquina/administración & dosificación , Infecciones por Coronavirus/mortalidad , Humanos , Hidroxicloroquina/administración & dosificación , Incidencia , Pandemias , Neumonía Viral/mortalidad , Enfermedades Reumáticas/tratamiento farmacológico
5.
Emerg Microbes Infect ; 9(1): 830-832, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-125318

RESUMEN

The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic.


Asunto(s)
Antimaláricos , Antirreumáticos , Antivirales , Betacoronavirus/efectos de los fármacos , Infecciones por Coronavirus/tratamiento farmacológico , Hidroxicloroquina , Neumonía Viral/tratamiento farmacológico , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Antimaláricos/uso terapéutico , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Antirreumáticos/uso terapéutico , Antivirales/administración & dosificación , Antivirales/efectos adversos , Antivirales/uso terapéutico , Ensayos Clínicos como Asunto , Infecciones por Coronavirus/epidemiología , Humanos , Hidroxicloroquina/administración & dosificación , Hidroxicloroquina/efectos adversos , Hidroxicloroquina/uso terapéutico , Comunicación Interdisciplinaria , Pandemias , Neumonía Viral/epidemiología , Reumatólogos
6.
Hellenic J Cardiol ; 61(1): 42-45, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-40673

RESUMEN

OBJECTIVE: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. METHODS: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. RESULTS: Trial results will be disseminated through peer-reviewed publications and conference presentations. CONCLUSION: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790).


Asunto(s)
Colchicina , Infecciones por Coronavirus , Cardiopatías , Pandemias , Neumonía Viral , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Betacoronavirus/aislamiento & purificación , Técnicas de Laboratorio Clínico/métodos , Colchicina/administración & dosificación , Colchicina/efectos adversos , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/fisiopatología , Cardiopatías/sangre , Cardiopatías/etiología , Cardiopatías/prevención & control , Humanos , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Neumonía Viral/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Evaluación de Síntomas/métodos , Troponina/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA